Saturday, July 12, 2025

Latest

Datametrex Secures Rights To Sell And Distribute Rapid COVID-19 Antigen Test Kits

Datametrex AI (TSXV: DM) this morning announced that it has secured the rights to sell and distribute a rapid antigen detection kit from South Korean manufacturer PCL Inc. The main benefit of the test is that with 97% accuracy, they produce results in as little as 5 to 10 minutes with no extra equipment being required for the consumer.

Datametrex AI's Logo

The test hosts advantages over others on the market solely as a result of the rapid testing nature of the product, combined with the lack of additional equipment being needed to conduct the test. The test is a method of measuring the presence of a COVID-19 infection via an in-vitro diagnostic medical device. It detects antigen of the SARS-CoV-2 virus from a persons oropharyngeal and nasopharyngeal secretions. Like a simple pregnancy test, if antigens are found a colored line appears in the T line area.

It’s said that the test has a clinical sensitivity, i.e., the ability to confirm the actual positive of the approved person, of 100%, and the clinical specificity, i.e the ability to confirm the actual negative of the negative person, of 97.78%. The antigen test has been awarded numerous certifications, including CE, Korea FDA, UNGM and more. It’s also been approved by the EU, Qatar, United Arab Emirates, India, Russia, Ecuador, Guatemala and Colombia.

“According to the manufacturer, PCL, this test can detect antigens of COVID-19 from a swab in the nose or throat and provide results in 10 minutes with over 97% accuracy. These almost-instant kits can be easily used at home. With the rise of cases in the United States and throughout the world, we at Datametrex believes it is critical to test and protect.”

Marshall Gunter, CEO of Datametrex

The strong benefit of the instant antigen kits that require no additional equipment, is that they can be conducted at home easily, with nearly instant results. This eliminates excessive wait times as high as 3-5 days or more previously experienced by individuals that have had other forms of COVID-19 tests performed.

Datametrex AI last traded at $0.15 on the TSX Venture.


FULL DISCLOSURE: DataMetrex AI Limited is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DataMetrex AI Limited on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Mergers Set the Stage for Uranium’s Growth Cycle | Forum-Baselode Merger

The Goal is Gold Production as Soon as Possible! | Gordon Robb – ESGOLD Corp.

Snowline Gold: The Multi Billion Dollar Valley PEA

Recommended

First Majestic Produces 7.9 Silver Equivalent Ounces In Q2, Lifts Production Guidance

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

Related News

Internet Of Things Books First Purchase Order For ThermalPass, Over 100 Inquiries Received On Product

Internet of Things Inc (TSXV: ITT) this morning released to the market that it has...

Tuesday, June 23, 2020, 09:14:52 AM

Selling COVID-19 Test Kits In Canada – The Daily Dive feat Marshall Gunter of Datametrex AI

This afternoon on The Daily Dive, Marshall Gunter, CEO of Datametrex AI (TSXV: DM) joins...

Thursday, December 17, 2020, 01:00:00 PM

Goldman Sachs Projects Strong US Economy In 2021, But Notes Significant Obstacles Ahead

As the US continues to battle its second, significantly more severe wave of the coronavirus...

Friday, November 13, 2020, 12:06:38 PM

Datametrex AI Sees Medi-Call Launch In-Person Care Beta

Following the launch of its Medi-Call mobile app just days ago, Datametrex AI (TSXV: DM)...

Monday, November 1, 2021, 08:12:45 AM

Rebound in Oil Demand Remains at Risk of Coronavirus Resurgence

As the global demand for oil dried up significantly during the height of the pandemic,...

Sunday, July 12, 2020, 07:17:00 PM